JP2015522601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015522601A5 JP2015522601A5 JP2015522100A JP2015522100A JP2015522601A5 JP 2015522601 A5 JP2015522601 A5 JP 2015522601A5 JP 2015522100 A JP2015522100 A JP 2015522100A JP 2015522100 A JP2015522100 A JP 2015522100A JP 2015522601 A5 JP2015522601 A5 JP 2015522601A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- subject
- disease
- macular degeneration
- onset
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000002780 macular degeneration Diseases 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 21
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 15
- 208000027073 Stargardt disease Diseases 0.000 claims description 13
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 13
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 12
- KPYSYYIEGFHWSV-UHFFFAOYSA-N Baclofen Chemical compound OC(=O)CC(CN)C1=CC=C(Cl)C=C1 KPYSYYIEGFHWSV-UHFFFAOYSA-N 0.000 claims description 10
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 10
- AFCGFAGUEYAMAO-UHFFFAOYSA-N acamprosate Chemical compound CC(=O)NCCCS(O)(=O)=O AFCGFAGUEYAMAO-UHFFFAOYSA-N 0.000 claims description 10
- 229960004047 acamprosate Drugs 0.000 claims description 10
- 229960000794 baclofen Drugs 0.000 claims description 10
- 208000011325 dry age related macular degeneration Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 230000033115 angiogenesis Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000000790 retinal pigment Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 238000013268 sustained release Methods 0.000 claims 3
- 239000012730 sustained-release form Substances 0.000 claims 3
- 239000005562 Glyphosate Substances 0.000 claims 1
- 201000007737 Retinal degeneration Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 claims 1
- 229940097068 glyphosate Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004258 retinal degeneration Effects 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 5
- 230000000366 juvenile effect Effects 0.000 description 3
- 208000008069 Geographic Atrophy Diseases 0.000 description 2
- 206010025421 Macule Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 210000001116 retinal neuron Anatomy 0.000 description 1
- 210000003583 retinal pigment epithelium Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672893P | 2012-07-18 | 2012-07-18 | |
| US61/672,893 | 2012-07-18 | ||
| PCT/EP2013/065209 WO2014013025A1 (en) | 2012-07-18 | 2013-07-18 | Baclofen and acamprosate based therapy of macular degeneration disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015522601A JP2015522601A (ja) | 2015-08-06 |
| JP2015522601A5 true JP2015522601A5 (enExample) | 2017-11-16 |
| JP6271539B2 JP6271539B2 (ja) | 2018-01-31 |
Family
ID=48794112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015522100A Expired - Fee Related JP6271539B2 (ja) | 2012-07-18 | 2013-07-18 | バクロフェン及びアカンプロセートに基づいた黄斑変性疾患の治療法 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9545389B2 (enExample) |
| EP (1) | EP2874617B1 (enExample) |
| JP (1) | JP6271539B2 (enExample) |
| KR (1) | KR20150058159A (enExample) |
| CN (1) | CN104780917B (enExample) |
| AU (1) | AU2013291970B2 (enExample) |
| BR (1) | BR112015001090A2 (enExample) |
| CA (1) | CA2879114A1 (enExample) |
| EA (1) | EA029157B1 (enExample) |
| ES (1) | ES2729208T3 (enExample) |
| IL (1) | IL236737B (enExample) |
| IN (1) | IN2015DN00820A (enExample) |
| MX (1) | MX364232B (enExample) |
| NZ (1) | NZ704280A (enExample) |
| SG (1) | SG11201500309VA (enExample) |
| WO (1) | WO2014013025A1 (enExample) |
| ZA (1) | ZA201500663B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2727587A1 (en) | 2012-10-30 | 2014-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| WO2015063140A1 (en) | 2013-10-30 | 2015-05-07 | Pharnext | Compositions, methods and uses for the treatment of diabetes and related conditions by controlling blood glucose level |
| MX2016010409A (es) | 2014-02-11 | 2016-11-30 | Pharnext | Combinacion de baclofeno, acamprosato y trigliceridos de cadena media para el tratamiento de trastornos neurologicos. |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002316231A1 (en) | 2002-02-19 | 2003-09-29 | Xenoport, Inc. | Methods for synthesis of prodrugs from 1-acyl-alkyl derivatives and compositions thereof |
| BRPI0413756A (pt) | 2003-08-20 | 2006-10-31 | Xenoport Inc | composto, métodos para tratar ou evitar espasticidade ou um sintoma de espasticidade, doença de refluxo gastro-esofágico, vìcio em droga, vìcio em ou abuso de álcool, ou vìcio em ou abuso de nicotina, e tosse ou êmese em um paciente, e, composição farmacêutica |
| US20050112210A1 (en) | 2003-09-12 | 2005-05-26 | Terry Grossman | Eye nutritional supplement |
| CN102702065A (zh) | 2003-12-30 | 2012-10-03 | 什诺波特有限公司 | 酰氧基烃基氨基甲酸酯前药及其中间体的合成 |
| TWI369982B (en) | 2007-01-11 | 2012-08-11 | Xenoport Inc | Sustained release oral dosage forms of a prodrug of r-baclofen and methods of treatment |
| JP2010532331A (ja) * | 2007-07-05 | 2010-10-07 | アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） | 抗痙攣医薬組成物 |
| US20090082464A1 (en) | 2007-09-07 | 2009-03-26 | Bernd Jandeleit | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| WO2009033069A1 (en) | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Simple pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| TW200932734A (en) | 2007-10-15 | 2009-08-01 | Xenoport Inc | Internally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
| US20090118365A1 (en) * | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
| US20100137442A2 (en) | 2008-02-01 | 2010-06-03 | Xenoport, Inc. | Sustained Release Particulate Oral Dosage Forms of (R)-Baclofen and Methods of Treatment |
| WO2009096985A1 (en) | 2008-02-01 | 2009-08-06 | Xenoport, Inc. | Sustained release particulate oral dosage forms of (r)-baclofen prodrugs and methods of treatment |
| WO2010089355A1 (en) * | 2009-02-04 | 2010-08-12 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Taurine or taurine-like substances for the prevention and treatment of a disease associated with retinal ganglion cell degeneration |
| KR20110117216A (ko) * | 2009-03-03 | 2011-10-26 | 제노포트 인코포레이티드 | Ｒ-바클로펜 전구약물의 서방형 경구 투약 형태 |
| EP2419401A2 (en) | 2009-04-17 | 2012-02-22 | XenoPort, Inc. | GAMMA-AMINO-BUTYRIC ACID DERIVATIVES AS GABAb RECEPTOR LIGANDS |
| KR101937782B1 (ko) * | 2011-03-01 | 2019-01-11 | 파넥스트 | 바클로펜 및 아캄프로세이트에 기초한 신경 장애의 치료 |
-
2013
- 2013-07-18 NZ NZ704280A patent/NZ704280A/en not_active IP Right Cessation
- 2013-07-18 AU AU2013291970A patent/AU2013291970B2/en not_active Ceased
- 2013-07-18 SG SG11201500309VA patent/SG11201500309VA/en unknown
- 2013-07-18 MX MX2015000777A patent/MX364232B/es active IP Right Grant
- 2013-07-18 WO PCT/EP2013/065209 patent/WO2014013025A1/en not_active Ceased
- 2013-07-18 ES ES13737622T patent/ES2729208T3/es active Active
- 2013-07-18 US US14/415,994 patent/US9545389B2/en not_active Expired - Fee Related
- 2013-07-18 EP EP13737622.4A patent/EP2874617B1/en not_active Not-in-force
- 2013-07-18 JP JP2015522100A patent/JP6271539B2/ja not_active Expired - Fee Related
- 2013-07-18 CA CA2879114A patent/CA2879114A1/en not_active Abandoned
- 2013-07-18 EA EA201500143A patent/EA029157B1/ru not_active IP Right Cessation
- 2013-07-18 CN CN201380048663.4A patent/CN104780917B/zh not_active Expired - Fee Related
- 2013-07-18 KR KR1020157004145A patent/KR20150058159A/ko not_active Ceased
- 2013-07-18 IN IN820DEN2015 patent/IN2015DN00820A/en unknown
- 2013-07-18 BR BR112015001090A patent/BR112015001090A2/pt not_active IP Right Cessation
-
2015
- 2015-01-15 IL IL236737A patent/IL236737B/en active IP Right Grant
- 2015-01-29 ZA ZA2015/00663A patent/ZA201500663B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2923685C (en) | Application of r-ketamine and salt thereof as pharmaceuticals | |
| JP2014505688A5 (enExample) | ||
| RU2018110647A (ru) | Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний | |
| BR112016015763B8 (pt) | preparação farmacêutica incluindo composto de ácido piridilaminocético, e, uso da mesma | |
| BRPI0819081A8 (pt) | Formulação oftálmica aquosa, processo para preparar a mesma, e, método para inibir, tratar ou prevenir doenças oculares e doença ou condição relacionada, em um paciente em necessidade de tal tratamento | |
| MX393855B (es) | Terapia de combinación que comprende un inhibidor de raf y trametinib | |
| EA201490163A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| BR112016025997A8 (pt) | compostos para tratamento de doenças e lesões oftalmológicas, uma composição farmacêutica e uma formulação oftálmica | |
| EA201490277A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| US20240366578A1 (en) | Treatment of pain and vasoconstriction | |
| HK1199726A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| BR112015009504A2 (pt) | inibidores de rock | |
| HK1219943A1 (zh) | 用於治疗眼科疾病和障害的取代3-苯基丙胺衍生物 | |
| JP7519359B2 (ja) | レシニフェラトキシンを投与することによってパーキンソン病を処置するための方法 | |
| CN110114083A (zh) | 一种预防和治疗脂肪肝的方法 | |
| JP2015512432A5 (enExample) | ||
| EA201100462A1 (ru) | Серосвязанные соединения для лечения офтальмологических заболеваний и расстройств | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| AU2017261303A1 (en) | Ophthalmic compositions | |
| WO2018005801A3 (en) | Novel non-systemic tgr5 agonists | |
| JP2015522601A5 (enExample) | ||
| WO2009003694A3 (en) | Method for treating diseases related to mitochondrial dysfunction | |
| JP2015522077A5 (enExample) | ||
| AU2019287528A1 (en) | Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |